Dr. Will Gibson and Dr. C. Michael Gibson discuss how p53 was once considered an undruggable target for cancer therapy.

A new article in the NEJM raises hope that there may be a path forward.

Dr. Will Gibson, an oncologist at Dana Farber Cancer Institute puts the findings in perspective and shares his exciting new findings and the path forward. 

Disclosures: TBD